Janssen, L.P.'s RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
5/20/2009 8:52:04 AM
More...
|
Janssen, L.P. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
5/19/2009 11:05:33 AM
More...
|
FDA Grants Approval for Use of Janssen, L.P.'s RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
5/18/2009 7:22:46 AM
More...
|
Janssen, L.P. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
12/10/2008 7:32:58 AM
More...
|
Janssen, L.P. Announces Launch of Authorized Generic for RISPERDAL(R)
7/1/2008 10:27:11 AM
More...
|
Janssen, L.P. Release: Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
2/4/2008 8:10:40 AM
More...
|
Janssen, L.P. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10/15/2007 9:25:54 AM
More...
|
Janssen, L.P. and Johnson and Johnson Pharmaceutical R&D (NJ) Release: FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8/22/2007 11:04:34 AM
More...
|
Janssen, L.P. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
5/23/2007 11:26:08 AM
More...
|
FDA Approves New Dose of Janssen, L.P. and Alkermes (ALKS)'s RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
4/13/2007 9:41:19 AM
More...
|
|